Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avatrombopag in Primary Immune Thrombocytopenia (ITP) in Adults (ITP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04890041
Recruitment Status : Recruiting
First Posted : May 18, 2021
Last Update Posted : May 18, 2021
Sponsor:
Information provided by (Responsible Party):
Zhang Lei, Institute of Hematology & Blood Diseases Hospital

Brief Summary:
This single-center study aims to study the efficacy and safety of avatrombopag in Chinese adult ITP patients. This study will be conducted in adult ITP patients who had not responded to eltrombopag or rhTPO in the previous treatment .

Condition or disease Intervention/treatment Phase
Primary Immune Thrombocytopenic Purpura Drug: Avatrombopag Not Applicable

Detailed Description:

The primary objective of this study was to evaluate the efficacy and safety of avatrombopag in adult ITP patients who had not responded to eltrombopag or rhTPO in the previous treatment.

20 eligible subjects will be enroll ed in this study.The dose will be adjusted according to the subject platelet count during the period from week 1 to week 8.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Avatrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults With Poor Efficacy of Eltrombopag or rhTPO: a Single-center, Prospective, One-arm Study
Estimated Study Start Date : May 30, 2021
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : December 31, 2021


Arm Intervention/treatment
Experimental: Treatment group
20 subjects will be enrolled with the indicated treatment dose of avatrombopag
Drug: Avatrombopag
The subjects will receive avatrombopag treatment with an initial dose once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until the 8th week of the study. The dose adjustment range is 20 mg~ per week to 40 mg per day to maintain the platelet level between 50×10^9/L and 150×10^9/L. If the platelet count does not reach to 30×10^9/L after taking avatrombopag 40 mg once a day for 4 consecutive weeks, the treatment will be stopped. If the platelet count is more than 400×10^9/L after taking avatrombopag 20 mg once a day for 2 consecutive weeks, the treatment will be stopped.
Other Name: TPORAs




Primary Outcome Measures :
  1. Treatment response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 2 ]
    Percentage of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at week 2 of treatment


Secondary Outcome Measures :
  1. Treatment response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 1, 3, 4, 6 and 8. ]
    Percentage of participants achieving a platelet count >=30×10^9/L and at least doubling of the baseline count at week 1,3,4,6 and 8 of treatment

  2. Treatment response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 8 ]
    Percentage of participants achieving a platelet count >=50×10^9/L at week 8 of treatment

  3. Time to Response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 8 ]
    Time to response is defined as time from the start of treatment to the first time of achieving a platelet count >=30×10^9/L and at least doubling of the baseline count during the whole 8 weeks

  4. Duration of response [ Time Frame: From the start of study treatment (Day 1) up to the end of week 8 ]
    Total duration of time a participant had a platelet count >=30×10^9/L

  5. Evaluation of effectiveness [ Time Frame: From the start of study treatment (Day 1) up to the end of week 8 ]
    Number of participants that reduced or discontinued baseline concomitant ITP medications during the whole 8 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women greater than or equal to 18 years of age.
  • Participants diagnosed with chronic primary immune thrombocytopenia (greater than or equal to 12 months duration) and an average of 2 platelet counts < 30x10^9/L at least 7 days, do not have evidence of other causes of thrombocytopenia (e.g., pseudothrombocytopenia, myeloid fibrosis). The physical exam should not suggest any other diseases which may cause thrombocytopenia other than ITP.
  • Previous treatment with Eltrombopag or rhTPO was ineffective (platelet count < 30x10^9/L after treatment, or platelet count increased less than twice the baseline value, or bleeding).
  • Prothrombin time/International Normalized Ratio and activated partial thromboplastin time must have been within 80% to 120% of the normal range with no history of hypercoagulable state.
  • Good compliance.

Exclusion Criteria:

  • Patients diagnosed with secondary immune thrombocytopenia or a history of systemic lupus erythematosus and antiphospholipid antibody syndrome.
  • A history of myelodysplastic syndrome (MDS), lymphoproliferative disease, myelodysplastic tumor, and leukemia.
  • A history of arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism) within 3 months before screening, and the following 2 or more risk factors: including estrogen hormone replacement therapy or contraceptive therapy, smoking, diabetes, hypercholesterolemia, high blood pressure medications, cancer or any other family history of arterial or venous thrombosis, or patients who were taking anticoagulants or antiplatelet drugs at the beginning of the screening.
  • Participants with a history of significant cardiovascular disease (e.g., congestive heart failure [CHF] New York Heart Association Grade III, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], coronary artery stent placement, angioplasty, coronary artery bypass grafting).
  • Hereditary prethrombotic syndromes (e.g., thrombin factor V Leiden mutation, prothrombin G20210A mutation, or hereditary antithrombin (ATIII) deficiency).
  • Participants with concurrent malignant tumor diseases.
  • Blood creatinine >1.2 times the upper limit of normal value (ULN) .
  • Participants with known allergy to avatrombopag or its excipients.
  • Women who are pregnant or who intend to become pregnant in the near future are excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04890041


Contacts
Layout table for location contacts
Contact: Wei Liu +82223909240 liuwei1@ihcams.ac.cn
Contact: Lei Zhang +82223909240 zhanglei1@ihcams.ac.cn

Locations
Layout table for location information
China, Tianjin
Institute of Hematology & Blood Diseases Hospital Recruiting
Tianjin, Tianjin, China, 300020
Contact: Lei Zhang, MD    +862223909240    zhanglei1@ihcams.ac.cn   
Contact: Lei Zhang    +82223909240    zhanglei1@ihcams.ac.cn   
Sponsors and Collaborators
Institute of Hematology & Blood Diseases Hospital
Investigators
Layout table for investigator information
Principal Investigator: Lei Zhang Institute of Hematology & Blood Diseases Hospital
Layout table for additonal information
Responsible Party: Zhang Lei, Professor/Vice director of Thrombosis &Hemostasis Center, Institute of Hematology & Blood Diseases Hospital
ClinicalTrials.gov Identifier: NCT04890041    
Other Study ID Numbers: SKX-ITP-001
First Posted: May 18, 2021    Key Record Dates
Last Update Posted: May 18, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Immune System Diseases
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Platelet Disorders
Hematologic Diseases
Blood Coagulation Disorders
Hemorrhage
Pathologic Processes
Skin Manifestations
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases